Who makes Fentanyl [Fentanyl WZF]?

Fentanyl [Fentanyl WZF] is developed by Medical University of Warsaw.

What development phase is Fentanyl [Fentanyl WZF] in?

Fentanyl [Fentanyl WZF] is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Fentanyl [Fentanyl WZF]

Medical University of Warsaw · FDA-approved active Small molecule Quality 0/100

Fentanyl WZF, developed by the Medical University of Warsaw, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Fentanyl [Fentanyl WZF]
Sponsor	Medical University of Warsaw
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fentanyl [Fentanyl WZF] CI brief — competitive landscape report
Fentanyl [Fentanyl WZF] updates RSS · CI watch RSS
Medical University of Warsaw portfolio CI